Free beta — full access, free until October 2026. No card, no auto-charge — paid plans are opt-in when they launch.
Company
STEMLINE THERAPEUTICS INC (0001264587)
Standardized SEC financial data for STEMLINE THERAPEUTICS INC — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0001264587 · Pharmaceutical Preparations.
Revenue growth (YoY)
-44.3%
Return on equity
-41.5%
Free cash flow
-$67.7M
Current ratio
8.01×
Ratios for fiscal year 2018, standardized from SEC filings.
Income statement
USD
FY2016
FY2017
FY2018
FY2019
Revenue
$1.0M
$898K
$500K
—
Cost of revenue
—
—
—
$4.9M
R&D expense
$27.9M
$50.2M
$47.7M
$50.7M
SG&A expense
$12.1M
$19.2M
$39.1M
$66.8M
Operating income
-$38.9M
-$68.6M
-$86.3M
Standardized from STEMLINE THERAPEUTICS INC's SEC filings — per-share figures split-adjusted. Full history via the API.